Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MI enters its October 20 earnings date having shed 10% in a week, while a cluster of insider selling over the past three months raises questions about internal confidence at levels the stock has not tested since before its mid-year surge.
The insider picture is the most striking element of the current setup. Director and substantial shareholder Madam Yong Shiao Voon sold 30 million shares across two days in late July at MYR 5.372, a transaction worth roughly MYR 161 million. Director Mr Teo Chee Kheong followed in early August, selling a further 100,000 shares at prices near MYR 5.71 to 5.76. Net of a single small unpriced purchase by substantial shareholder Mr Oh Kuang Eng in March, insider activity over the trailing 90 days amounts to a net disposal of 60.4 million shares worth approximately MYR 163 million. That is a significant volume of stock moved by people close to the company, at prices meaningfully above where MI now trades at MYR 5.21.
Despite that selling pressure, the borrow market tells a curiously relaxed story. Availability is exceptionally loose: more than 22 million shares remain available to borrow, representing roughly 2,400% of current short interest. That figure has risen sharply over the past week, up nearly 47%, as lenders add supply. The ORTEX short score has drifted lower, sitting at 39.8 on October 2, down from around 40.6 for most of the prior two weeks, placing MI in the 43rd percentile for short positioning relative to its sector. Cost to borrow is a different matter: at 35.4%, it is structurally elevated and has been running in the 32% to 38% range since May 2025, suggesting that while available supply is ample, the cost of maintaining a short position remains punishing. The net picture is one where short conviction exists but is expensive, and the borrow pool is not being meaningfully tapped.
On the Street, the most recent analyst consensus points to a mean price target of MYR 6.06, which implies roughly 16% upside from current levels. That data, however, carried a staleness flag of 34 days and no recent target changes are recorded in the dataset, so the target should be treated as a directional reference rather than a live read. Valuation multiples have compressed over the past month: the price-to-earnings ratio has fallen by about 2.8 points over 30 days to 27.7, and price-to-book has shed 0.38 points to 3.7. The EV/EBITDA of 19 has similarly eased. Factor scores paint a mixed picture: MI ranks in the 89th percentile on dividend score and the 87th on days-to-cover, but earnings momentum over the next 12 months forward ranks in only the 8th percentile, the weakest single reading in the factor set. That combination, generous near-term income yield, stretched short-covering dynamics, but weak forward earnings revision momentum, is not a straightforwardly bullish setup ahead of a print.
Earnings history adds texture. The August 21 result produced a 4% one-day drop and the stock was still down 3% five days later. The July 20 event was the outlier: a 26% single-day gain that carried through to a 21% five-day move, consistent with the August note about a 34% surge in net profit. The May print produced a modest 3.6% gain on the day. Three of the four most recent releases landed within a few percent of flat; the July spike was the exception rather than the pattern.
Peer performance this week deepens the underperformance story. VITROX gained 5.5% on the week and AEMULUS added 2.4%, while MPI fell 4% and UNISEM dropped 7.9%. MI's 10% weekly decline puts it at the soft end of a mixed peer group, rather than tracking a sector-wide selloff.
The October 20 print is therefore less about whether the company can repeat the dramatic July beat, and more about whether the current pace of insider disposals reflects something specific about the business trajectory that the market has not yet priced in.
See the live data behind this article on ORTEX.
Open MI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.